Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Target Price at $19.00

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $19.00.

A number of research analysts recently weighed in on ENTA shares. Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating for the company in a report on Tuesday, August 6th.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $11.28 on Tuesday. The firm has a market capitalization of $238.90 million, a price-to-earnings ratio of -1.81 and a beta of 0.59. Enanta Pharmaceuticals has a 52-week low of $8.08 and a 52-week high of $17.80. The company’s fifty day moving average is $13.19 and its two-hundred day moving average is $13.60.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.36. The company had revenue of $17.97 million for the quarter, compared to analyst estimates of $17.44 million. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. Enanta Pharmaceuticals’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.27) earnings per share. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -5.3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total transaction of $64,785.93. Following the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at $361,499.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, insider Scott T. Rottinghaus sold 4,299 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the sale, the insider now directly owns 23,988 shares of the company’s stock, valued at $361,499.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the sale, the insider now directly owns 21,717 shares of the company’s stock, valued at $370,926.36. The disclosure for this sale can be found here. 13.64% of the stock is owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Enanta Pharmaceuticals by 7.5% in the first quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after buying an additional 134,292 shares during the last quarter. Farallon Capital Management LLC grew its holdings in Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock valued at $36,579,000 after buying an additional 70,000 shares in the last quarter. Pennant Investors LP acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $330,000. Cubist Systematic Strategies LLC raised its holdings in Enanta Pharmaceuticals by 65.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares during the period. Finally, Quest Partners LLC purchased a new stake in Enanta Pharmaceuticals in the fourth quarter valued at approximately $146,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.